2-(2-{cis-3-[2-(3-butyl-1-heptylureido)ethoxy]cyclohexyl}ethyl)-3-methylbutyric acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(2-{cis-3-[2-(3-butyl-1-heptylureido)ethoxy]cyclohexyl}ethyl)-3-methylbutyric acid
• 英文别名: 2-[2-[(1R,3R)-3-[2-[butylcarbamoyl(heptyl)amino]ethoxy]cyclohexyl]ethyl]-3-methylbutanoic acid
• 化学式: C₂₇H₅₂N₂O₄
• 分子量: 468.721
• InChiKey: CECWJQDKXZJVID-AEAWWFNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  33
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220261A1

  公开（公告）日：2004-11-04

  The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  本发明涉及芳基环烷基取代衍生物及其生理上可接受的盐和生理功能衍生物。所述的化合物为I式，其中基团如定义所述，以及其生理上可接受的盐和制备它们的方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• US7173151B2
  申请人：——

  公开号：US7173151B2

  公开（公告）日：2007-02-06